Zepp Health Corp: Form 20-F for the period ended Dec 31, 2022
Filed with the SEC on Apr 24, 2023 and accepted by EDGAR at Apr 24, 2023, 16:53 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2022-01-01 to 2022-12-31 | $600.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2022-01-01 to 2022-12-31 | $484.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2022-01-01 to 2022-12-31 | $116.4m | us-gaap:GrossProfit |
| Research and development | 12 months2022-01-01 to 2022-12-31 | $75.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2022-01-01 to 2022-12-31 | −$59.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2022-01-01 to 2022-12-31 | $8.3m | us-gaap:InterestExpense |
| Income tax | 12 months2022-01-01 to 2022-12-31 | −$9.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$41.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | −$0.17 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −$0.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-01-01 to 2022-12-31 | 246,283,328 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$114.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $1.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2022-01-01 to 2022-12-31 | $5.8m | us-gaap:PaymentsOfDividends |
| Share repurchases | 12 months2022-01-01 to 2022-12-31 | $7.7m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-12-31 | $128.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $428.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $763.7m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $241.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $374.5m | us-gaap:Liabilities |
| Long-term debt | At period end2022-12-31 | $99.2m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2022-12-31 | $387.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-23-049064. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.